This is a humanized IgG4 antibody using the same sequences as the therapeutic antibody concizumab. It targets the tissue factor pathway inhibitor (TFPI), and improves hemostasis in individuals with hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of TFPI, one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and blocking the factor Xa (FXa) active site. When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis. The concizumab mechanism of action does not interfere with the regulation of coagulation downstream of TFPI.